CRISPR Therapeutics: Analysis Of And Update On The B-Thalassemia Franchise – Seeking Alpha
Seeking Alpha |
CRISPR Therapeutics: Analysis Of And Update On The B-Thalassemia Franchise
Seeking Alpha The company recently submitted a CTA for CTX-001 (the potential treatment for the blood disorder Beta-thalassemia). It's the first application for the CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a potentially revolutionary platform to launch a … |
